

AUG 29 2001

Chapter 1 – Summary Information

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92

The assigned 510(k) number is: K012561.

1. Submitter name, address, contact

Ortho-Clinical Diagnostics, Inc.
100 Indigo Creek Drive
Rochester, New York 14626-5101
(716) 453-4469

Contact Person: Susan Werner

Date 510(k) prepared: August 6, 2001

2. Device Name

Trade or Proprietary Name: *Vitros* Immunodiagnostic Products Anti-HCV Controls
Common Name: Anti-HCV controls
Classification Name: 21CFR 862.1660 Quality Control Material (Assayed and Unassayed).

3. Predicate Device

The *Vitros* Immunodiagnostic Products Anti-HCV Controls are substantially equivalent to Boston Biomedica, Inc. ACCURUN 1® Multi-Marker Positive Control (BK930027).

4. Device Description

The *Vitros* Immunodiagnostic System uses luminescence as the signal in the qualitative detection of anti-HCV in human serum and plasma. Coated microwells are used as the solid phase separation system.

The system is comprised of three main elements:

1. The *Vitros* Immunodiagnostic Products range of products, in this case *Vitros* Immunodiagnostic Products Anti-HCV Reagent Pack and *Vitros* Immunodiagnostic Products Calibrator, which are combined by the *Vitros* Immunodiagnostic System to perform a *Vitros* assay. The *Vitros* Immunodiagnostic Products Anti-HCV Reagent Pack and Calibrator have been submitted for FDA review in PMA P010021.

510(k) Summary, continued.

2. The *Vitros* Immunodiagnostic System - instrumentation, which provides automated use of the immunoassay kits. The *Vitros* Immunodiagnostic System was cleared for market by a separate 510(k) pre-market notification (K962919).
3. Common reagents used by the *Vitros* System in each assay. The *Vitros* Immunodiagnostic Products Signal Reagent and *Vitros* Immunodiagnostic Products Universal Wash Reagent were cleared as part of the *Vitros* Immunodiagnostic Products Total T3 510(k) pre-market notification (K964310).

The *Vitros* System and common reagents are dedicated specifically only for use with the *Vitros* Immunodiagnostic Products range of immunoassay products.

5. Device Intended Use

The *Vitros* Anti-HCV Controls are intended for use in monitoring the performance of the *Vitros* ECi Immunodiagnostic System when used for the *in vitro* qualitative detection of immunoglobulin G antibody to hepatitis C virus (anti-HCV) in human serum and plasma (heparin, EDTA or citrate). The performance of the *Vitros* Immunodiagnostic Products Anti-HCV Controls has not been established with any other anti-HCV assays.

6. Comparison to Predicate Device

The *Vitros* Immunodiagnostic Products Anti-HCV Controls are substantially equivalent to Boston Biomedica, Inc. ACCURUN 1® Multi-Marker Positive Control (BK930027).

Table 1 lists the similarities and differences of the device characteristics between the *Vitros* Anti-HCV Controls and the predicate device.

Table 1 Characteristics of the Controls

Characteristics	New Device	Predicate Device
Intended use	For use in monitoring the performance of the <i>Vitros</i> ECi Immunodiagnostic System when used for the <i>in vitro</i> qualitative detection of immunoglobulin G antibody to hepatitis C virus (anti-HCV) in human serum and plasma (heparin, EDTA or citrate). The performance of the <i>Vitros</i> Immunodiagnostic Products Anti-HCV Controls has not been established with any other anti-HCV assays.	ACCURUN 1® controls are intended to estimate laboratory testing precision and can be used to detect errors in laboratory testing procedures. ACCURUN 1® Multi-Marker Positive Controls have been formulated for use with <i>in vitro</i> diagnostic test kits for the detection of antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV 1 and 2), antibodies to Human T-Lymphotropic Virus Types I and II (HTLV I and II), antibodies to Hepatitis B Core Antigen (HBcAg), antibodies to Hepatitis C Virus (HCV), antibodies to Cytomegalovirus (CMV), and Hepatitis B Surface Antigen. A negative control for these analytes is available separately from BBI®.
Matrix of controls	Human serum with added antimicrobial agents	Human serum or plasma with added stabilizers and preservative.
Control levels	Positive and negative	Positive
Expected values	Each control has a quoted mean value derived from a minimum of 10 assays and a standard deviation anticipated for single determinations of each control in a number of different laboratories using different reagent lots. Values are lot specific.	As stated in the package insert, ACCURUN 1® controls do not have assigned values, but are formulated to produce positive reactivity in the listed manufacturer's assays. Specific levels of reactivity will vary among different manufacturers' assays, different procedures, different reagent lot numbers, and different laboratories. Each laboratory should establish its own range of acceptable values for each analyte.

7. Conclusions

The information presented in the pre-market notification demonstrates that the *Vitros* Anti-HCV Controls are substantially equivalent to the predicate device Boston Biomedica, Inc. ACCURUN 1® Multi-Marker Positive Control which was cleared by FDA (BK930027).

The information presented in the premarket notification provide a reasonable assurance that the *Vitros* Anti-HCV Controls are safe and effective for the stated intended use.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

AUG 29 2001

Ms. Susan Werner
Regulatory Affairs Associate
Ortho-Clinical Diagnostics, Inc.
100 Indigo Creek Drive
Rochester, NY 14626-5101

Re: K012561
Trade/Device Name: *Vitros* Immunodiagnostic Products Anti-HCV Controls
Regulation Number: 21 CFR 862.1660
Regulatory Class: I
Product Code: JJX, MJY, MJX
Dated: August 6, 2001
Received: August 8, 2001

Dear Ms. Werner:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.


A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in dark ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Statement of Intended Use

Page 1 of 1

510(k) Number (if known):

K012561

Device Name:

Vitros Immunodiagnostic Products Anti-HCV Controls

Indications for Use:

For use in monitoring the performance of the *Vitros* ECI Immunodiagnostic System when used for the *in vitro* qualitative detection of immunoglobulin G antibody to hepatitis C virus (anti-HCV) in human serum and plasma (heparin, EDTA or citrate). The performance of the *Vitros* Immunodiagnostic Products Anti-HCV Controls has not been established with any other anti-HCV assays.

Woody Dubois
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K012561

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)